Xie X, et al. - Researchers sought to comprehensively explore the value applying positron emission tomography (PET) to predict the impact of molecularly targeted therapy in solid tumors. They performed a systematic search for potentially relevant studies from the time of inception to February 2017. Findings suggested favorability of PET to predict the prognosis of molecularly targeted therapy for solid tumors. Inorder to predict clinical outcome, PET assessment within 2 weeks could be useful. A decrease in maximal standard uptake value (SUVmax), which was associated with a significantly prolonged progression-free survival (PFS), overall survival (OS), and time to progression (TTP) was displayed by PET response group vs PET nonresponse group.